Heather Corbo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Heather Corbo has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- David M. Salerno
Department of Pharmacy NewYork‐Presbyterian Hospital New York New York USA
4 shared publications - Justin K. Chen
Department of Pharmacy Children's Healthcare of Atlanta Atlanta Georgia USA
4 shared publications Anastasia Anamisis
Department of Pharmacy, NewYork-Presbyterian Hospital, New York City, New York, USA
2 shared publications- Danielle Kovac
Department of Pharmacy New York Presbyterian Hospital New York New York USA
2 shared publications - Douglas L. Jennings
Thomas J. Long School of Pharmacy University of the Pacific Sacramento California USA
2 shared publications - Jason Choe
Department of Pharmacy New York Presbyterian Hospital New York City New York USA
2 shared publications
Latest Publications
- 20 March 2023
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 69 (5) , e205-e211
Bivalirudin Compared to Heparin as the Primary Anticoagulant in Pediatric Berlin Heart Recipients
Bivalirudin has been used in increasing frequency as an alternative to unfractionated heparin (UFH) in pediatric recipients of Berlin Heart EXCOR ventricular assist devices (VAD). This single-center, retrospective review characterizes anticoagulant trends and outcomes in pediatric Berlin Heart VAD recipients implanted between September 1, 2013, and August 31, 2021, anticoagulated with either bivalirudin or UFH. Thirty-one patients were included; 65% who received bivalirudin and 35% who received UFH. The median age was 2.9 years, included 64.5% females, with 61.3% of patients diagnosed with dilated cardiomyopathy and 25.8% of patients with congenital heart disease. Therapeutic anticoagulation was achieved sooner in the bivalirudin group compared to UFH via anti-Xa monitoring (median 5.7 and 69.5 hours, respectively, p < 0.001). Bivalirudin had a greater number of therapeutic values comparatively to UFH (52% and 24%, respectively; p < 0.001) and a superior number of hours in the therapeutic range (67% and 32%, respectively; p < 0.001). Secondary outcomes were similar among the two groups, apart from greater chest tube output (UFH), more frequent events of elevated plasma-free hemoglobin (bivalirudin), and more frequent elevated inflammatory markers postimplant (bivalirudin). Prevalence of pump replacements secondary to significant clot burden and prevalence of stroke was comparable. In this patient cohort, bivalirudin demonstrated greater anticoagulation stability comparatively to UFH. Multicenter collaboration would be necessary to identify whether this further translates into improved patient outcomes.
- 20 March 2023
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 69 (5) , e205-e211
Bivalirudin Compared to Heparin as the Primary Anticoagulant in Pediatric Berlin Heart Recipients
Bivalirudin has been used in increasing frequency as an alternative to unfractionated heparin (UFH) in pediatric recipients of Berlin Heart EXCOR ventricular assist devices (VAD). This single-center, retrospective review characterizes anticoagulant trends and outcomes in pediatric Berlin Heart VAD recipients implanted between September 1, 2013, and August 31, 2021, anticoagulated with either bivalirudin or UFH. Thirty-one patients were included; 65% who received bivalirudin and 35% who received UFH. The median age was 2.9 years, included 64.5% females, with 61.3% of patients diagnosed with dilated cardiomyopathy and 25.8% of patients with congenital heart disease. Therapeutic anticoagulation was achieved sooner in the bivalirudin group compared to UFH via anti-Xa monitoring (median 5.7 and 69.5 hours, respectively, p < 0.001). Bivalirudin had a greater number of therapeutic values comparatively to UFH (52% and 24%, respectively; p < 0.001) and a superior number of hours in the therapeutic range (67% and 32%, respectively; p < 0.001). Secondary outcomes were similar among the two groups, apart from greater chest tube output (UFH), more frequent events of elevated plasma-free hemoglobin (bivalirudin), and more frequent elevated inflammatory markers postimplant (bivalirudin). Prevalence of pump replacements secondary to significant clot burden and prevalence of stroke was comparable. In this patient cohort, bivalirudin demonstrated greater anticoagulation stability comparatively to UFH. Multicenter collaboration would be necessary to identify whether this further translates into improved patient outcomes.
- Open Access
- 30 December 2022
- Published by Elsevier in American Journal of Transplantation
- Vol. 22 (11) , 2682-2688
COVID-19 therapeutics and outcomes among solid organ transplant recipients during the Omicron BA.1 era
- 30 December 2022
- Published by Elsevier in American Journal of Transplantation
- Vol. 22 (11) , 2682-2688
Open AccessCOVID-19 therapeutics and outcomes among solid organ transplant recipients during the Omicron BA.1 era
- 27 November 2022
- Published by Wiley in Clinical Transplantation
- Vol. 37 (2) , e14858
Immune cell function assay and T lymphocyte counts lack association with rejection or infection in pediatric heart transplant recipients
Introduction: Immune cell function assay (ICFA) and CD3 lymphocyte counts have been considered to be useful in discerning the overall intensity of immunosuppression in pediatric orthotopic heart transplant (OHT) recipients.Methods: The aim of this retrospective analysis was to evaluate trends of ICFA and CD3 lymphocyte counts and their association with adverse outcomes post‐OHT.Results: A total of 381 ICFA and 493 CD3 laboratory values obtained in 78 patients within six months post‐OHT were analyzed. There were 14 patients treated for biopsy‐proven acute rejection, four of whom had ISHLT grade 2R/3A rejection. In patients with rejection versus those without, CD3 and ICFA values were 122 (IQR 74.5–308) cells/mm2 and 224.5 (IQR 132–343.5) ng/ml compared to 231.8 (IQR 68–421) cells/m2 and 191 (IQR 81.5–333) ng/mL (p = NS for both). Twenty‐six patients had at least one detectable cytomegalovirus or Epstein‐Barr virus DNAemia within the study timeframe. In patients with viremia versus those without, CD3 and ICFA values were 278.5 (IQR 68–552) cells/mm2 and 130 (IQR 48–284) ng/ml compared to 195 (IQR 74.5–402.5) cells/mm2 and 212 (IQR 89–342) ng/ml (p = NS for both).Conclusions: No association was found between these immune markers and adverse outcomes. In the absence of larger pediatric studies justifying the role of these tests in identifying elevated risk profiles post OHT, we do not recommend their routine use.
- 27 November 2022
- Published by Wiley in Clinical Transplantation
- Vol. 37 (2) , e14858
Immune cell function assay and T lymphocyte counts lack association with rejection or infection in pediatric heart transplant recipients
Introduction: Immune cell function assay (ICFA) and CD3 lymphocyte counts have been considered to be useful in discerning the overall intensity of immunosuppression in pediatric orthotopic heart transplant (OHT) recipients.Methods: The aim of this retrospective analysis was to evaluate trends of ICFA and CD3 lymphocyte counts and their association with adverse outcomes post‐OHT.Results: A total of 381 ICFA and 493 CD3 laboratory values obtained in 78 patients within six months post‐OHT were analyzed. There were 14 patients treated for biopsy‐proven acute rejection, four of whom had ISHLT grade 2R/3A rejection. In patients with rejection versus those without, CD3 and ICFA values were 122 (IQR 74.5–308) cells/mm2 and 224.5 (IQR 132–343.5) ng/ml compared to 231.8 (IQR 68–421) cells/m2 and 191 (IQR 81.5–333) ng/mL (p = NS for both). Twenty‐six patients had at least one detectable cytomegalovirus or Epstein‐Barr virus DNAemia within the study timeframe. In patients with viremia versus those without, CD3 and ICFA values were 278.5 (IQR 68–552) cells/mm2 and 130 (IQR 48–284) ng/ml compared to 195 (IQR 74.5–402.5) cells/mm2 and 212 (IQR 89–342) ng/ml (p = NS for both).Conclusions: No association was found between these immune markers and adverse outcomes. In the absence of larger pediatric studies justifying the role of these tests in identifying elevated risk profiles post OHT, we do not recommend their routine use.
- 15 January 2022
- Published by Wiley in Clinical Transplantation
- Vol. 36 (3) , e14594
Nitazoxanide treatment for norovirus infection in solid organ transplant recipients
- 15 January 2022
- Published by Wiley in Clinical Transplantation
- Vol. 36 (3) , e14594
Nitazoxanide treatment for norovirus infection in solid organ transplant recipients